Wall Street Zen Upgrades Biomea Fusion (NASDAQ:BMEA) to Hold

Analysts see potential in the biotech company's cancer drug pipeline.

Mar. 30, 2026 at 5:25am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, heavy machinery and equipment used in the banking and financial industries, rendered in a high-contrast, cinematic style that conveys a sense of industrial power and institutional stability without using any literal currency, charts, or branding.The upgrade of Biomea Fusion's stock rating reflects growing investor confidence in the biotech company's ability to develop innovative cancer therapies through its specialized drug discovery platform.Carlsbad Today

Biomea Fusion (NASDAQ:BMEA), a clinical-stage biopharmaceutical company focused on developing small molecule therapies that target epigenetic regulators in cancer, has been upgraded from a 'sell' rating to a 'hold' rating by equities research analysts at Wall Street Zen. The upgrade comes as several other research firms have also weighed in on the company's lead drug candidate, BMF-219, an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.

Why it matters

The upgrade from Wall Street Zen and the generally positive sentiment from other analysts suggest growing optimism around Biomea Fusion's drug development efforts, which could signal potential upside for the company's stock if its pipeline continues to progress. As a clinical-stage biotech, Biomea Fusion's future performance will largely hinge on the success of its lead and future drug candidates.

The details

Wall Street Zen upgraded Biomea Fusion from a 'sell' rating to a 'hold' rating in a research note issued on Saturday. Other research firms have also weighed in on the company, with Rodman & Renshaw initiating coverage with a 'buy' rating and $8 price target, and D. Boral Capital reiterating a 'buy' rating with a $12 price target. Weiss Ratings, on the other hand, maintained a 'sell (e+)' rating on the stock. Citigroup also lifted its price target on Biomea Fusion from $6 to $7, while maintaining a 'buy' rating.

  • Wall Street Zen issued its upgrade on Saturday, March 30, 2026.
  • Rodman & Renshaw initiated coverage on Biomea Fusion on Tuesday, January 13th.
  • D. Boral Capital reiterated its 'buy' rating and $12 price target on Wednesday, March 25th.
  • Weiss Ratings maintained its 'sell (e+)' rating on Wednesday, January 21st.
  • Citigroup lifted its price target on Biomea Fusion on Friday, March 29th.

The players

Wall Street Zen

An equities research firm that upgraded Biomea Fusion's stock rating from 'sell' to 'hold'.

Rodman & Renshaw

A research firm that initiated coverage on Biomea Fusion with a 'buy' rating and $8 price target.

D. Boral Capital

A research firm that reiterated its 'buy' rating and $12 price target on Biomea Fusion.

Weiss Ratings

A research firm that maintained its 'sell (e+)' rating on Biomea Fusion.

Citigroup

A research firm that lifted its price target on Biomea Fusion from $6 to $7 while maintaining a 'buy' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

The upgrade from Wall Street Zen and the generally positive sentiment from other analysts suggest growing optimism around Biomea Fusion's drug development efforts, which could signal potential upside for the company's stock if its pipeline continues to progress. As a clinical-stage biotech, Biomea Fusion's future performance will largely hinge on the success of its lead and future drug candidates.